CLL: Maintenance Lenalidomide Has Limited Feasibility

Share this content:
No significant difference in progression-free survival between patients who received maintenance therapy after bendamustine-rituximab induction.
No significant difference in progression-free survival between patients who received maintenance therapy after bendamustine-rituximab induction.

There was no significant difference in progression-free survival between patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) who received maintenance therapy after bendamustine-rituximab induction compared with no maintenance, a study published in the British Journal of Haematology has shown.1

Although bendamustine plus rituximab has demonstrated high response rates in relapsed/refractory CLL/SLL, progression-free survival afterwards is less than 18 months. Therefore, researchers sought to determine if maintenance lenalidomide after benadmustine-rituximab induction could improve progression-free survival in this patient population.

For the study, researchers enrolled 34 patients with relapsed/refractory CLL/SLL who had received 1 to 5 prior chemotherapy regimens. Of those, 11 had confirmed presence of 17p and/or 11q deletions.

Participants received 6 cycles of bendamustine plus rituximab, and patients who achieved at least a minor response then received lenalidomide 5 to 10 mg/day for twelve 28-day cycles.

Results showed that 74% completed 6 cycles of induction therapy, and 56% achieved a response. Those patients received maintenance lenalidomide, but only 6 patients completed 12 cycles of maintenance therapy. The high discontinuation rate was primarily due to hematological and infectious toxicities.

Researchers also found that median progression-free survival was 18.3 months with maintenance therapy compared with 15.2 months without maintenance; however, the difference was not significant.

RELATED: CYP3A7 Allele May Worsen Outcomes in Patients With Several Cancer Types

The researchers hypothesize that lenalidomide maintenance may be more feasible and effective in the first-line treatment setting, which is currently being evaluated in an ongoing trial.


  1. Chang JE, Havighurst T, Kim K, et al. Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: a Wisconsin Oncology Network Study [published online ahead of print February 23, 2016]. Br J Haematol. doi: 10.1111/bjh.13957.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs